Daniel D. Billadeau, Ph.D.
The research of Daniel D. Billadeau, Ph.D., evolves from a long-standing interest in the mechanisms that control normal and abnormal cell growth. Many of the proteins involved in normal cellular processes are mutated or hijacked during pathological situations, resulting in immunodeficiency or cancer.
Understanding the consequences of these changes in the context of normal and abnormal cellular activity will ultimately lead to a better understanding of their normal cellular roles, but also may lead to the identification of novel targets for better treatment of human diseases such as cancer, immunodeficiency and neurodegenerative diseases.
Significance to patient care
Pancreatic cancer remains an incurable disease. Thus, a more mechanistic understanding of the biology of the disease will likely lead to the identification of targets that can be used in therapy.
In fact, recent work in Dr. Billadeau's laboratory on a kinase that regulates pancreatic cancer cell survival and growth has resulted in a clinical trial using a novel small molecule inhibitor of this kinase. Moreover, efforts by Dr. Billadeau and his team aimed at identifying new targets in cancer stem cells may lead to better treatment options that would eliminate this chemoresistant population of cancer cells.
Senior Research Fellow, Department of Immunology, Laboratory of Paul J. Leibson
Department of Immunology, Laboratory of Paul J. Leibson
Genetics and Cell Biology
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.